Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric B Haura

Showing results (81-90 of 213) with videos related to

Pageof 22
Sort By:
Nucleic Acid Therapeutics|July 21, 2022
Inhibition of Epidermal Growth Factor Receptor Signaling by Antisense Oligonucleotides as a Novel Approach to Epidermal Growth Factor Receptor InhibitionThushara W Madanayake, Eric A Welsh, Lancia N F Darville, et al.
BJR Artificial Intelligence|May 1, 2026
Does artificial intelligence need companionship to assist in drug discovery? The Kirsten rat sarcoma virus studyMourad Stitou, John M Koomen, Denis J Imbody, et al.
Cancer|June 18, 2025
An examination of factors associated with disparities in clinical trial eligibility guided by the Socioecological ModelYayi Zhao, Rossybelle P Amorrortu, J Kevin Hicks, et al.
Journal of Proteome Research|September 30, 2016
APOSTL: An Interactive Galaxy Pipeline for Reproducible Analysis of Affinity Proteomics DataBrent M Kuenzi, Adam L Borne, Jiannong Li, et al.
British Journal of Cancer|March 19, 2019
Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistanceBen C Creelan, Jhanelle E Gray, Tawee Tanvetyanon, et al.
Proteomics|September 1, 2020
Lowering Sample Requirements to Study Tyrosine Kinase Signaling Using Phosphoproteomics with the TMT Calibrator ApproachBin Fang, Victoria Izumi, Lily L Remsing Rix, et al.
Proteomics. Clinical Applications|February 14, 2015
Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicineElisa Baldelli, Eric B Haura, Lucio Crinò, et al.
Molecular Carcinogenesis|January 20, 2015
Interleukin polymorphisms associated with overall survival, disease-free survival, and recurrence in non-small cell lung cancer patientsNicholas T Woods, Alvaro N Monteiro, Zachary J Thompson, et al.
Oncotarget|November 29, 2017
A Bayesian pick-the-winner design in a randomized phase II clinical trialDung-Tsa Chen, Po-Yu Huang, Hui-Yi Lin, et al.
Carcinogenesis|February 1, 2014
SHP2E76K mutant promotes lung tumorigenesis in transgenic miceValentina E Schneeberger, Noreen Luetteke, Yuan Ren, et al.
Pageof 22

Showing results (81-90 of 213) with videos related to

Sort By:
Pageof 22
Nucleic Acid Therapeutics|July 21, 2022
Inhibition of Epidermal Growth Factor Receptor Signaling by Antisense Oligonucleotides as a Novel Approach to Epidermal Growth Factor Receptor InhibitionThushara W Madanayake, Eric A Welsh, Lancia N F Darville, et al.
BJR Artificial Intelligence|May 1, 2026
Does artificial intelligence need companionship to assist in drug discovery? The Kirsten rat sarcoma virus studyMourad Stitou, John M Koomen, Denis J Imbody, et al.
Cancer|June 18, 2025
An examination of factors associated with disparities in clinical trial eligibility guided by the Socioecological ModelYayi Zhao, Rossybelle P Amorrortu, J Kevin Hicks, et al.
Journal of Proteome Research|September 30, 2016
APOSTL: An Interactive Galaxy Pipeline for Reproducible Analysis of Affinity Proteomics DataBrent M Kuenzi, Adam L Borne, Jiannong Li, et al.
British Journal of Cancer|March 19, 2019
Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistanceBen C Creelan, Jhanelle E Gray, Tawee Tanvetyanon, et al.
Proteomics|September 1, 2020
Lowering Sample Requirements to Study Tyrosine Kinase Signaling Using Phosphoproteomics with the TMT Calibrator ApproachBin Fang, Victoria Izumi, Lily L Remsing Rix, et al.
Proteomics. Clinical Applications|February 14, 2015
Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicineElisa Baldelli, Eric B Haura, Lucio Crinò, et al.
Molecular Carcinogenesis|January 20, 2015
Interleukin polymorphisms associated with overall survival, disease-free survival, and recurrence in non-small cell lung cancer patientsNicholas T Woods, Alvaro N Monteiro, Zachary J Thompson, et al.
Oncotarget|November 29, 2017
A Bayesian pick-the-winner design in a randomized phase II clinical trialDung-Tsa Chen, Po-Yu Huang, Hui-Yi Lin, et al.
Carcinogenesis|February 1, 2014
SHP2E76K mutant promotes lung tumorigenesis in transgenic miceValentina E Schneeberger, Noreen Luetteke, Yuan Ren, et al.
Pageof 22